The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the ...

Ofatumumab, a fully human anti-CD20 monoclonal antibody, is a disease-modifying therapy (DMT) approved for the treatment of ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home ...

Novartis AG ( VTX:NOVN ) has announced that it will be increasing its dividend from last year's comparable payment ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 13 and set a price target of ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health ...

American football’s elite National Football League (NFL) has brought in US medicine company Novartis as the property's ...